{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T07:53:41Z","timestamp":1759564421417},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7363","type":"journal-article","created":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T22:09:48Z","timestamp":1484431788000},"page":"203-206","source":"Crossref","is-referenced-by-count":4,"title":["A Suspected Case of an Alveolar Haemorrhage Caused by Dasatinib"],"prefix":"10.2169","volume":"56","author":[{"given":"Yoritake","family":"Sakoda","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, St. Mary's Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yojiro","family":"Arimori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, St. Mary's Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, St. Mary's Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, St. Mary's Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. O&apos;Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500-4505, 2005.","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010.","DOI":"10.1056\/NEJMoa1002315"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123: 494-500, 2014.","DOI":"10.1182\/blood-2013-06-511592"},{"key":"4","unstructured":"4. SPRYCEL<sup>\u00ae<\/sup> Drug interview form version9 Britol-Myers Squibb."},{"key":"5","unstructured":"5. Nishikawa A, Fujiwara S, Hatano K, et al. A case of pulmonary and urinary bleedings caused by dasatinib in posttransplant reccurent ph-ALL. Jpn J Clin Hematol 50: 1168, 2009 (in Japanese)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lassence AD, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 151: 157-163, 1995.","DOI":"10.1164\/ajrccm.151.1.7812547"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Seo JB, Im JG, Chung JW, et al. Pulmonary vasculitis: the spectrum of radiological findings. Br J Radiol 73: 1224-1231, 2000.","DOI":"10.1259\/bjr.73.875.11144805"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Primack SL, Miller RR, Muller NL. Diffuse pulmonary hemorrhage: clinical, pathologic, and imaging features. Am J Roentgenol 164: 295-300, 1995.","DOI":"10.2214\/ajr.164.2.7839958"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Seely JM, Effmann EL, Muller NL. High-resolution CT of pediatric lung disease: imaging findings. Am J Roentgenol 168: 1269-1275, 1997.","DOI":"10.2214\/ajr.168.5.9129425"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Green RJ, Ruoss SJ, Kraft SA, et al. Pulmonary capillaritis and alveolar hemorrhage-update on diagnosis and management. Chest 10: 1305-1316, 1996.","DOI":"10.1378\/chest.110.5.1305"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Erdogan D, Kocaman O, Oflaz H, et al. Alveolar hemorrhage associated with warfarin therapy: a case report and literature review. Int J Cardiovasc Imaging 20: 155-159, 2004.","DOI":"10.1023\/B:CAIM.0000014101.06445.66"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Dhillon SS, Singh D, Doe N, et al. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 116: 1485-1488, 1999.","DOI":"10.1378\/chest.116.5.1485"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Iskandar SB, Abi-Saleh B, Keith RL, et al. Amiodarone-induced alveolar hemorrhage. South Med J 99: 383-387, 2006.","DOI":"10.1097\/01.smj.0000208971.43461.bb"},{"key":"14","unstructured":"14. Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 18: 243-252, 2001."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Schwartz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med 25: 133-140, 2004.","DOI":"10.1016\/S0272-5231(03)00139-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kelly K, Swords R, Mahalingam D, et al. Serosal inflammation (pleural and pericardial effusions) related to tyrosin kinase inhibitors. Target Oncol 4: 99-105, 2009.","DOI":"10.1007\/s11523-009-0110-4"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23: 1398-1405, 2009.","DOI":"10.1038\/leu.2009.46"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Qiu ZY, Xu W, Li Jy. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther 15: 247-255, 2014.","DOI":"10.4161\/cbt.27310"},{"key":"19","unstructured":"19. Schwarz M, King TE Jr. Interstitial Lung Disease 5th ed. People&apos;s Medical Publishing House, USA, 2011: 637-688."},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884, 2013.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nagata Y, Fukuda S, Kobayashi T, et al. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase. Int J Hematol 91: 539-541, 2010.","DOI":"10.1007\/s12185-010-0526-8"},{"key":"22","unstructured":"22. Furuta R, Kawaguchi T, Miyagawa E, et al. A CML pt experiencing imatinib-induced interstitial pneumonia (IP) had recurrent IP with nilotinib. Jpn J Clin Hematol 54: 1386, 2013 (in Japanese, Abstract in English)."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/2\/56_56.7363\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T08:16:45Z","timestamp":1498378605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/2\/56_56.7363\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7363","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}